vestimИзвестия Национальной академии наук Беларуси. Серия медицинских наукProceedings of the National Academy of Sciences of Belarus, Medical series1814-60232524-2350The Republican Unitary Enterprise Publishing House "Belaruskaya Navuka"vestim-330Research ArticleКЛИНИЧЕСКАЯ И ЭКСПЕРИМЕНТАЛЬНАЯ МЕДИЦИНАCLINICAL AND EXPERIMENTAL MEDICINEДОЛГОСРОЧНЫЕ ПОКАЗАТЕЛИ ВЫЖИВАЕМОСТИ ДЕТЕЙ И ПОДРОСТКОВ С НЕМЕТАСТАТИЧЕСКИМИ ФОРМАМИ САРКОМЫ ЮИНГА В РЕСПУБЛИКЕ БЕЛАРУСЬLOCALIZED SKELETAL EWING’S SARCOMA IN THE REPUBLIC OF BELARUS: LONG-TERM SURVIVAL RATES FOR PEDIATRIC PATIENTSКиселёвЛ. П.KisialeuL. P.

канд. мед. наук, зав. онкогематологическим отделением № 3

leonslight@mail.ruАлейниковаО. В.AleinikovaO. V.

чл.-кор. НАН Беларуси, д-р мед. наук, профессор

aleinikova2004@mail.ruРеспубликанский научно-практический центр детской онкологии, гематологии и иммунологииBelarusian Research Center for Pediatric Oncology, Hematology and Immunology20161301201704714Copyright © Киселёв Л.П., Алейникова О.В., 20172017Киселёв Л.П., Алейникова О.В.Kisialeu L.P., Aleinikova O.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://vestimed.belnauka.by/jour/article/view/330

Саркома Юинга (СЮ) – вторая по частоте встречаемости опухоль костной ткани у пациентов детского и подросткового возраста. Целью исследования была оценка долгосрочных показателей выживаемости при локализованных (неметастатических) формах СЮ и анализ характеристик пациентов с благоприятными и  неблагоприятными исходами заболевания. В анализ включены 72 пациента с СЮ, получивших лечение в Республиканском научно-практическом центре детской онкологии, гематологии и иммунологии Республики Беларусь с 1999 по 2014 г. Для пациентов с локализованными формами СЮ 15-летняя общая выживаемость составила 64,6  %. Изученные клинико-патологические характеристики пациентов (пол, возраст, уровень лактатдегидрогеназы, размер и локализация опухоли и др.) не позволяли прогнозировать исход заболевания перед началом терапии. Показатели долгосрочной выживаемости пациентов с локализованными формами СЮ в Беларуси соответствуют стандартам стран с развитой системой здравоохранения. Для своевременной коррекции плана системной терапииперед началом лечения необходимы новые маркеры для стратификации пациентов на группы риска.

Ewing sarcoma (ES) is the second most common primary bone tumor in children. The aim of this study was to evaluate the clinical outcomes and long-term survival for pediatric patients with localized bone ES. 72 previously untreated patients with localized ES, reported to the sub-cancer registry database from 1999 to 2014, were evaluated. Survival rate was estimated via the Kaplan-Meier method and compared using log-rank tests and Cox proportional hazard models. 15-year overall survival was 64.6  %. Common clinical prognostic factors (age, sex, tumors volume, response to treatment and others) were not different between patients with favorable and unfavorable outcomes.Treatment results for patients with localized ES from the Republic of Belarus comply with generally accepted standards. Searching for new predictive markers is necessary for early detection of resistant to conventional treatment patients.

саркома Юинга у детейкостная локализациялечениевыживаемостьlocalized bone Ewing’s sarcomapediatric patientstreatmentsurvivalReferencesДостижения детской онкологии и гематологии в Республике Беларусь // О. В. Алейникова [и др.] // Актуальные вопросы детской онкологии и гематологии: материалы VIII междунар. симп. – Минск, 2000. – C. 3–8.Aleinikova, O. V., Potapnev, M. P., Sytskevich, O. N., Petrovich, S. V., Ismail-Zade, R. S. and Strongin, Y. S. (2000) “Advances Pediatric Oncology and Hematology in Belarus”, Topical issues of Pediatric Oncology and Hematology: Materials VIII Intern. Symp. Minsk, BY, pp. 3-8.Суконко, О. Г. Организационно-методическая помощь, оказываемая государственным учреждением РНПЦ ОМР им. Н. Н. Александрова организациям здравоохранения в Республике Беларусь / О. Г. Суконко, Н. А. Антоненкова // Онкол. журн. – 2011. – № 20. – С. 42–45.Sukonko, O. G. and Antonenkova, N. A. (2011) “Organizational and methodological assistance provided by the state institution Republican Center of Oncology and Medical Radiology named N. N. Alexandrov for healthcare organizations in the Republic of Belarus”, Onkologicheskii zhurnal [Cancer Journal], no. 20, pp. 42-45.Неоперируемый рак щитовидной железы: эффективность диагностики и выживаемость / Ю. Е. Демидчик [и др.] // Онкол. журн. – 2008. – № 8. – С. 9–21.Demidchik, Y. Y., Pisarenko, A. M., Fridman, M. V., Baragina, Z. N., Mankovskaya, S. V. and Papok, V. E. (2011) “Impossible for operation thyroid cancer: effectiveness of diagnosis and survival”, Onkologicheskii zhurnal [Cancer Journal], no. 8, pр. 9-21.Роль молекулярных часов в патогенезе и терапии злокачественных новообразований / Э. А. Жаврид [и др.] // Мед. панорама. – 2011. – № 7. – С. 19–23.Zhavrid, E. A., Antonenkova, N., Prokhorov, V. I. and Lappo, S. V. (2011) “The role of the molecular clock in the pathogenesis and therapy of malignant tumors”, Meditsinskaya panorama [Medical panorama], no. 7, pp. 19-23.Characteristics and outcomes of patients with Ewing sarcoma over 40 years of a geat diagnosis / E. E. Karski [et al.] // Cancer Epidemiol. – 2013. – N 37. – P. 29–33.Karski, E. E., Matthay, K. K., Neuhaus, J. M., Goldsby, R. E. and Dubois, S. G. (2013) “Characteristics and outcomes of patients with Ewing sarcoma over 40 years of a geat diagnosis”, Cancer Epidemiology, no. 37, pp. 29-33.Prognostic factors in Ewing’s tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing’s Sarcoma Study Group / S. J. Cotterill [et al.] // J. Clin. Oncol. – 2000. – N 18. – P. 3108–3114.Cotterill, S. J., Ahrens, S., Paulussen, M., Jürgens, H. F., Voûte, P. A., Gadner, H. and Craft, A. W. (2000) “Prognostic factors in Ewing’s tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing’s Sarcoma Study Group”, Journal of Clinical Oncology, no. 18, pp. 3108-3114.Prognostic factors for local and distant control in Ewing sarcoma family of tumors / C. Rodriguez-Galindo [et al.] // Ann. Oncol. – 2008. – N 19. – P. 814–820.Rodriguez-Galindo, C., Navid, F., Liu T., Billups, C. A., Rao, B. N. and Krasin, M. J. (2008) “Prognostic factors for local and distant control in Ewing sarcoma family of tumors”, Annals of Oncology, no. 19, pp. 814-820.Analysis of prognostic factors in Ewing sarcoma using a population-based cancerregistry / J. Lee [et al.] // Cancer. – 2010. – N 116. – P. 1964–1973.Lee J., Hoang, B. H., Ziogas A. and Zell, J. A. (2010) “Analysis of prognostic factors in Ewing sarcoma using a populationbased cancerregistry”, Cancer, no. 116, pp. 1964-1973.Clinical features and outcomes in patients with extraskeletal Ewing sarcoma / M. A. Applebaum [et al.] // Cancer. – 2011. – Vol. 117 (13). – P. 3027–3032.Applebaum, M. A., Worch, J., Matthay, K. K., Goldsby, R., Neuhaus, J., West, D. C. and Dubois, S. G. (2011) “Clinical features and outcomes in patients with extraskeletal Ewing sarcoma”, Cancer, vol. 117 (13), pp. 3027-3032.Petrovich S., Aleĭnikova O., Shumikhina T. Epidemiological aspects of childhood onco-hematological morbidity in the Republic of Belarus] // Vopr. Onkol. – 2002. – Vol. 48 (3). – P. 301–305.Petrovich, S., Aleinikova, O. and Shumikhina, T. (2002) “Epidemiological aspects of childhood onco-hematological morbidity in the Republic of Belarus”, Voprosy Onkologii, vol. 48 (3), pp. 301-305.Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: a selective review of Intergroup Rhabdomyosarcoma Study Group experience and rationale for Intergroup Rhabdomyosarcoma Study V / R. B. Raney [et al.] //J. Pediatr. Hematol. Oncol. – 2001. – N 23. – P. 215–220.Raney, R. B., Anderson, J. R., Barr, F. G., Donaldson, S. S., Pappo, A. S., Qualman, S. J., Wiener, E. S., Maurer, H. M. and Crist, W. M. (2001) “Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: a selective review of Intergroup Rhabdomyosarcoma Study Group experience and rationale for Intergroup Rhabdomyosarcoma Study V”, Journal of Pediatric Hematology/Oncology, no. 23, pp. 215-220.Results of the EICESS-92 Study: two randomized trials of Ewing’s sarcoma treatment – cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients / M. Paulussen [et al.] // J. Clin. Oncol. – 2008. – N 26. – P. 4385–4393.Paulussen, M., Craft, A.W., Lewis, I., Hackshaw, A., Douglas, C., Dunst, J., Schuck, A., Winkelmann, W., Köhler, G., Poremba, C., Zoubek, A., Ladenstein, R., van den Berg H., Hunold, A., Cassoni, A., Spooner, D., Grimer, R., Whelan, J., McTiernan A. and Jürgens, H. (2008) “Results of the EICESS-92 Study: two randomized trials of Ewing’s sarcoma treatment – cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients”, Journal of Clinical Oncology, no. 26, pp. 4385-4393.Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumours: a Children’s Oncology Group study / L. Granowetter [et al.] // J. Clin. Oncol. – 2009. – N 27. – P. 2536–2541.Granowetter, L., Womer, R., Devidas, M., Krailo, M., Wang, C., Bernstein, M., Marina, N., Leavey, P., Gebhardt, M., Healey, J., Shamberger, R. C., Goorin, A., Miser, J., Meyer, J., Arndt, C. A., Sailer, S., Marcus, K., Perlman, E., Dickman, P. and Grier, H. E. (2009) “Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumours: a Children’s Oncology Group study”, Journal of Clinical Oncology, no. 27, pp. 2536-2541.Impact of high-dose busulfan plus melphalan as consolidation in metastatic Ewing tumours: a study by the Societe Francaise des Cancers de l’Enfant / O. Oberlin [et al.] // J. Clin. Oncol. – 2006. – N 24. – P. 3997–4002.Oberlin, O., Rey, A., Desfachelles, A. S., Philip, T., Plantaz, D., Schmitt, C., Plouvier, E., Lejars, O., Rubie, H., Terrier, P. and Michon, J. (2006) “Impact of high-dose busulfan plus melphalan as consolidation in metastatic Ewing tumours: a study by the Societe Francaise des Cancers de l’Enfant”, Journal of Clinical Oncology, no. 24, pp. 3997-4002.Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin and etoposide (VIDE) in the treatment of Ewing tumours in the EURO-E.W.I.N.G. 99 clinical trial / C. Juergens [et al.] // Pediatr. Blood Cancer. – 2006. – N 47. – P. 22–29.Juergens, C., Weston, C., Lewis, I., Whelan, J., Paulussen, M., Oberlin, O., Michon, J., Zoubek, A., Juergens, H. and Craft, A. (2006) “Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin and etoposide (VIDE) in the treatment of Ewing tumours in the EURO-E.W.I.N.G. 99 clinical trial”, Pediatr Blood Cancer, no. 47, pp. 22-29.Biomarkers in Ewing sarcoma: the promise and challenge of personalized medicine. A report from the Children’s Oncology Group / S. Neerav [et al.]; The COG Ewing Sarcoma Biology Committee // Frontiers in Oncol. – 2013. – N 3. – P. 1–13.Neerav, S., Joshua, D., Schiffman, D. R., Davis, I. J., Womer, R. B., Lessnick, S. L. and Lawlor, E. R. (2013) “Biomarkers in Ewing sarcoma: the promise and challenge of personalized medicine. A report from the Children’s Oncology Group”, Frontiers in oncology, no. 3, pp. 1-13. 14

The authors declare that there are no conflicts of interest present.